MedPath

Evaluation of the gastrointestinal effects of breads containing in situ produced arabinoxylan-oligosaccharides in healthy volunteers

Completed
Conditions
Gastrointestinal effects of arabinoxylan-oligosaccharides
Digestive System
Registration Number
ISRCTN17344943
Lead Sponsor
Puracor NV (Belgium)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
25
Inclusion Criteria

1. Age between 18 and 46 years
2. Good general health (determined by self-assessment)
3. Regular eating habit (3 meals per day during at least 5 days per week)

Exclusion Criteria

1. History of abdominal surgery
2. Intake of antibiotics less than two months before the start of the study
3. Medical treatments influencing gut transit less than 2 weeks before the start of the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total short chain fatty acid concentrations in faeces were significantly higher upon consumption of WR+ (wheat/rye bread with in situ produced AXOS) compared to intake of W- (wheat flour bread without in situ produced AXOS). Butyrate levels were 1.7 times higher after consumption of WR+ than in the run-in or wash-out period (W- consuming periods). Consumption of WR+ tended to increase selectively the faecal concentration of bifidobacteria (P = 0.06) relative to intake of W-.
Secondary Outcome Measures
NameTimeMethod
1. Urinary phenol and p-cresol excretion were significantly lower after WR+ intake compared to WR- (wheat/rye bread without in situ produced AXOS)<br>2. Average stool frequency and the composite stool frequency/consistency parameter were increased after intake of WR+ compared to WR-. No adverse effects on gastrointestinal symptoms were reported during WR+ intake.
© Copyright 2025. All Rights Reserved by MedPath